StockNews.AI
BTMD
StockNews.AI
160 days

Biote Reports Fourth Quarter and Full Year 2024 Financial Results

1. Biote (BTMD) reported Q4 2024 revenue of $49.8 million. 2. The company's gross profit margin improved significantly to 71.8%.

Earnings
-25.12%Current Return
VS
-1.33%S&P 500
$4.103/12 04:28 PM EDTEvent Start
$3.0703/13 10:43 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The significant revenue growth and high gross profit margin indicate strong business performance, which could drive stock price appreciation, similar to prior quarters where positive financial announcements correlated with stock gains.

How important is it?

The article highlights key financial metrics that are critical for investor decisions, indicating a strong likelihood of impacting BTMD's market perception and price.

Why Short Term?

Immediate investor reactions to positive financial results often lead to short-term price movements, as seen in previous earnings reports across similar companies.

Related Companies

NASDAQ: INSPNASDAQ: HRCNASDAQ: HIMS
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $49.8 million Procedure revenue of $36.6 million Gross profit margin of 71.8% Net in.

Related News